Biological therapies for asthma
Five to 10% of asthma patients remain symptomatic and/or have asthma attacks despite adequate inhaled and systemic therapy. Eosinophilic, type 2 airway inflammation is seen in half of these patients with severe asthma. There is now convincing evidence that type 2 inflammation drives susceptibility t...
Päätekijät: | Couillard Castonguay, S, Pavord, I |
---|---|
Muut tekijät: | Janes, S |
Aineistotyyppi: | Book section |
Kieli: | English |
Julkaistu: |
Elsevier
2021
|
Samankaltaisia teoksia
-
Fractional exhaled nitric oxide non-suppression in asthma
Tekijä: Couillard Castonguay, S
Julkaistu: (2021) -
Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype OxfoRd Asthma attaCk risk scaLE (ORACLE)
Tekijä: Couillard Castonguay, S, et al.
Julkaistu: (2022) -
Fluticasone furoate: CAPTAIN of fluticasones in type 2 inflammatory asthma
Tekijä: Couillard, S, et al.
Julkaistu: (2022) -
Asthma in pregnancy: An update
Tekijä: Couillard, S, et al.
Julkaistu: (2020) -
How I do it: workup of severe asthma
Tekijä: Couillard, S, et al.
Julkaistu: (2021)